Eintrag weiter verarbeiten
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis
Gespeichert in:
| Zeitschriftentitel: | Arthritis & Rheumatism |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Arthritis & Rheumatism, 40, 1997, 9, S. 1644-1652 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Cantwell, Mark J. Hua, Tinh Zvaifler, Nathan J. Kipps, Thomas J. Cantwell, Mark J. Hua, Tinh Zvaifler, Nathan J. Kipps, Thomas J. |
|---|---|
| author |
Cantwell, Mark J. Hua, Tinh Zvaifler, Nathan J. Kipps, Thomas J. |
| spellingShingle |
Cantwell, Mark J. Hua, Tinh Zvaifler, Nathan J. Kipps, Thomas J. Arthritis & Rheumatism Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis Pharmacology (medical) Immunology Rheumatology Immunology and Allergy |
| author_sort |
cantwell, mark j. |
| spelling |
Cantwell, Mark J. Hua, Tinh Zvaifler, Nathan J. Kipps, Thomas J. 0004-3591 1529-0131 Wiley Pharmacology (medical) Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.1780400914 <jats:title>Abstract</jats:title><jats:p><jats:italic>Objective</jats:italic>. To examine the expression and function of CD95 (Fas) and its ligand in rheumatoid arthritis (RA).</jats:p><jats:p><jats:italic>Methods</jats:italic>. We used flow cytometry and reverse transcriptase‐polymerase chain reaction methods to assess lymphocyte expression of CD95 and its ligand. We also examined whether lymphocytes could undergo Fas‐mediated apoptosis with anti‐CD95 monoclonal antibody (MAb) or human Fas ligand‐expressing fibroblasts, and if synovial fluid contained a soluble factor(s) that could inhibit such interactions. Finally, we determined whether anti‐CD3 MAb could induce synovial T cells to express the Fas ligand in vitro.</jats:p><jats:p><jats:italic>Results</jats:italic>. Nearly all RA synovial fluid or synovial tissue lymphocytes expressed CD95 and could be induced to undergo apoptosis by CD95 crosslinking. We did not detect a soluble inhibitor in RA synovial fluid that could account for the survival of CD95+ synovial cells in vivo. Instead, we detected little or no expression of Fas ligand by RA synovial lymphocytes. However, we could induce such cells to express Fas ligand with anti‐CD3 MAb or phorbol ester and ionomycin in vitro.</jats:p><jats:p><jats:italic>Conclusion</jats:italic>. There is ineffective clearance of activated cells in the RA joint due to deficient expression of the Fas ligand.</jats:p> Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis Arthritis & Rheumatism |
| doi_str_mv |
10.1002/art.1780400914 |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMTc4MDQwMDkxNA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMTc4MDQwMDkxNA |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 1997 |
| imprint_str_mv |
Wiley, 1997 |
| issn |
0004-3591 1529-0131 |
| issn_str_mv |
0004-3591 1529-0131 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
cantwell1997deficientfasligandexpressionbysynoviallymphocytesfrompatientswithrheumatoidarthritis |
| publishDateSort |
1997 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Arthritis & Rheumatism |
| source_id |
49 |
| title |
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_unstemmed |
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_full |
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_fullStr |
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_full_unstemmed |
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_short |
Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_sort |
deficient fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| topic |
Pharmacology (medical) Immunology Rheumatology Immunology and Allergy |
| url |
http://dx.doi.org/10.1002/art.1780400914 |
| publishDate |
1997 |
| physical |
1644-1652 |
| description |
<jats:title>Abstract</jats:title><jats:p><jats:italic>Objective</jats:italic>. To examine the expression and function of CD95 (Fas) and its ligand in rheumatoid arthritis (RA).</jats:p><jats:p><jats:italic>Methods</jats:italic>. We used flow cytometry and reverse transcriptase‐polymerase chain reaction methods to assess lymphocyte expression of CD95 and its ligand. We also examined whether lymphocytes could undergo Fas‐mediated apoptosis with anti‐CD95 monoclonal antibody (MAb) or human Fas ligand‐expressing fibroblasts, and if synovial fluid contained a soluble factor(s) that could inhibit such interactions. Finally, we determined whether anti‐CD3 MAb could induce synovial T cells to express the Fas ligand in vitro.</jats:p><jats:p><jats:italic>Results</jats:italic>. Nearly all RA synovial fluid or synovial tissue lymphocytes expressed CD95 and could be induced to undergo apoptosis by CD95 crosslinking. We did not detect a soluble inhibitor in RA synovial fluid that could account for the survival of CD95+ synovial cells in vivo. Instead, we detected little or no expression of Fas ligand by RA synovial lymphocytes. However, we could induce such cells to express Fas ligand with anti‐CD3 MAb or phorbol ester and ionomycin in vitro.</jats:p><jats:p><jats:italic>Conclusion</jats:italic>. There is ineffective clearance of activated cells in the RA joint due to deficient expression of the Fas ligand.</jats:p> |
| container_issue |
9 |
| container_start_page |
1644 |
| container_title |
Arthritis & Rheumatism |
| container_volume |
40 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343208681799690 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:48:01.369Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Deficient+Fas+ligand+expression+by+synovial+lymphocytes+from+patients+with+rheumatoid+arthritis&rft.date=1997-09-01&genre=article&issn=1529-0131&volume=40&issue=9&spage=1644&epage=1652&pages=1644-1652&jtitle=Arthritis+%26+Rheumatism&atitle=Deficient+Fas+ligand+expression+by+synovial+lymphocytes+from+patients+with+rheumatoid+arthritis&aulast=Kipps&aufirst=Thomas+J.&rft_id=info%3Adoi%2F10.1002%2Fart.1780400914&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343208681799690 |
| author | Cantwell, Mark J., Hua, Tinh, Zvaifler, Nathan J., Kipps, Thomas J. |
| author_facet | Cantwell, Mark J., Hua, Tinh, Zvaifler, Nathan J., Kipps, Thomas J., Cantwell, Mark J., Hua, Tinh, Zvaifler, Nathan J., Kipps, Thomas J. |
| author_sort | cantwell, mark j. |
| container_issue | 9 |
| container_start_page | 1644 |
| container_title | Arthritis & Rheumatism |
| container_volume | 40 |
| description | <jats:title>Abstract</jats:title><jats:p><jats:italic>Objective</jats:italic>. To examine the expression and function of CD95 (Fas) and its ligand in rheumatoid arthritis (RA).</jats:p><jats:p><jats:italic>Methods</jats:italic>. We used flow cytometry and reverse transcriptase‐polymerase chain reaction methods to assess lymphocyte expression of CD95 and its ligand. We also examined whether lymphocytes could undergo Fas‐mediated apoptosis with anti‐CD95 monoclonal antibody (MAb) or human Fas ligand‐expressing fibroblasts, and if synovial fluid contained a soluble factor(s) that could inhibit such interactions. Finally, we determined whether anti‐CD3 MAb could induce synovial T cells to express the Fas ligand in vitro.</jats:p><jats:p><jats:italic>Results</jats:italic>. Nearly all RA synovial fluid or synovial tissue lymphocytes expressed CD95 and could be induced to undergo apoptosis by CD95 crosslinking. We did not detect a soluble inhibitor in RA synovial fluid that could account for the survival of CD95+ synovial cells in vivo. Instead, we detected little or no expression of Fas ligand by RA synovial lymphocytes. However, we could induce such cells to express Fas ligand with anti‐CD3 MAb or phorbol ester and ionomycin in vitro.</jats:p><jats:p><jats:italic>Conclusion</jats:italic>. There is ineffective clearance of activated cells in the RA joint due to deficient expression of the Fas ligand.</jats:p> |
| doi_str_mv | 10.1002/art.1780400914 |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hcnQuMTc4MDQwMDkxNA |
| imprint | Wiley, 1997 |
| imprint_str_mv | Wiley, 1997 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0004-3591, 1529-0131 |
| issn_str_mv | 0004-3591, 1529-0131 |
| language | English |
| last_indexed | 2024-03-01T16:48:01.369Z |
| match_str | cantwell1997deficientfasligandexpressionbysynoviallymphocytesfrompatientswithrheumatoidarthritis |
| mega_collection | Wiley (CrossRef) |
| physical | 1644-1652 |
| publishDate | 1997 |
| publishDateSort | 1997 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Arthritis & Rheumatism |
| source_id | 49 |
| spelling | Cantwell, Mark J. Hua, Tinh Zvaifler, Nathan J. Kipps, Thomas J. 0004-3591 1529-0131 Wiley Pharmacology (medical) Immunology Rheumatology Immunology and Allergy http://dx.doi.org/10.1002/art.1780400914 <jats:title>Abstract</jats:title><jats:p><jats:italic>Objective</jats:italic>. To examine the expression and function of CD95 (Fas) and its ligand in rheumatoid arthritis (RA).</jats:p><jats:p><jats:italic>Methods</jats:italic>. We used flow cytometry and reverse transcriptase‐polymerase chain reaction methods to assess lymphocyte expression of CD95 and its ligand. We also examined whether lymphocytes could undergo Fas‐mediated apoptosis with anti‐CD95 monoclonal antibody (MAb) or human Fas ligand‐expressing fibroblasts, and if synovial fluid contained a soluble factor(s) that could inhibit such interactions. Finally, we determined whether anti‐CD3 MAb could induce synovial T cells to express the Fas ligand in vitro.</jats:p><jats:p><jats:italic>Results</jats:italic>. Nearly all RA synovial fluid or synovial tissue lymphocytes expressed CD95 and could be induced to undergo apoptosis by CD95 crosslinking. We did not detect a soluble inhibitor in RA synovial fluid that could account for the survival of CD95+ synovial cells in vivo. Instead, we detected little or no expression of Fas ligand by RA synovial lymphocytes. However, we could induce such cells to express Fas ligand with anti‐CD3 MAb or phorbol ester and ionomycin in vitro.</jats:p><jats:p><jats:italic>Conclusion</jats:italic>. There is ineffective clearance of activated cells in the RA joint due to deficient expression of the Fas ligand.</jats:p> Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis Arthritis & Rheumatism |
| spellingShingle | Cantwell, Mark J., Hua, Tinh, Zvaifler, Nathan J., Kipps, Thomas J., Arthritis & Rheumatism, Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis, Pharmacology (medical), Immunology, Rheumatology, Immunology and Allergy |
| title | Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_full | Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_fullStr | Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_full_unstemmed | Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_short | Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_sort | deficient fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| title_unstemmed | Deficient Fas ligand expression by synovial lymphocytes from patients with rheumatoid arthritis |
| topic | Pharmacology (medical), Immunology, Rheumatology, Immunology and Allergy |
| url | http://dx.doi.org/10.1002/art.1780400914 |